China’s NMPA Approves World’s First Factor XI Inhibitor

This is a notable regulatory first: a novel mechanism and target reaching market anywhere, with China acting before other jurisdictions. The immediate impact falls on stroke-prevention treatment pathways and the clinicians who would combine it with existing standards, given the emphasis on long-term management. The open questions are whether approvals elsewhere follow and how the combination use described by the regulator is reflected in real-world practice.